Hormone optimization: how the routes differ and when each fits
The overview for hormone work: replacement versus stimulation, what a provider weighs when choosing between them, and what gets measured.
Key takeaways
- Replacement and stimulation are different clinical decisions. HRT and TRT replace a hormone; sermorelin and tesamorelin prompt your own pituitary.
- Low testosterone is diagnosed on symptoms plus at least two morning measurements on separate days, not on one low reading.
- Reading of the HRT evidence changed after the first Women's Health Initiative headlines: timing, age at start and formulation all move the risk picture.
- Hormone symptoms overlap heavily with thyroid problems, poor sleep and low iron, which is why a panel rather than a single marker settles the question.
- Replacement therapy starts with labs. HRT and TRT are not prescribed without them.
- Hormone optimization is not anti-aging. Correcting a real deficiency often improves how you feel; that is a different claim from slowing aging.
Hormone support is a category rather than a single therapy, and most of the confusion around it comes from treating it as one thing. Testosterone, estrogen, thyroid, cortisol and DHEA-S all influence energy, recovery, mood and body composition, and they produce overlapping symptoms. A meaningful evaluation looks at the whole pattern rather than one isolated value.
Two broad routes sit inside the category. Replacement gives the body a hormone it is no longer producing at the level it used to. Stimulation prompts the body to produce more of its own. They are not interchangeable, they are not judged by the same evidence, and a prescribing provider does not substitute one for the other.
The goal is not to push a number to the top of a range. It is to move the pattern toward where symptoms resolve and long-term health is protected.
Replacement: HRT and TRT
HRT covers estrogen and progesterone therapy for perimenopause and menopause. The early Women's Health Initiative coverage shaped a generation of assumptions, and the reading has since become more specific: time since menopause, age at start and the formulation used all change the risk and benefit picture. That is why it belongs in a conversation with a prescriber rather than in a yes or no answer on a web page.
TRT is testosterone replacement where low testosterone is confirmed. The Endocrine Society guideline is built around at least two morning total testosterone measurements on separate days, because levels peak in the morning and vary day to day. Monitoring usually covers testosterone, hematocrit, estradiol, and PSA where age appropriate. Hematocrit is on that list because testosterone raises red cell production.
Stimulation: growth hormone secretagogues
Sermorelin and tesamorelin act on the pituitary instead of replacing a hormone, which is why the release pattern stays closer to the body's own rhythm. Tesamorelin is the better evidenced of the two, with FDA approval for HIV-associated lipodystrophy and trial data behind it. Sermorelin has a long clinical history and a well described mechanism, with far less modern trial data than tesamorelin.
Neither is a treatment for low testosterone, and neither is a substitute for HRT in menopause. They answer a different question.
Which route a provider considers
It follows the pattern, not the preference. Menopausal and perimenopausal symptoms point toward HRT. Confirmed low testosterone with matching symptoms points toward TRT. Body composition, recovery and sleep complaints in someone whose sex hormones already sit in range point somewhere else entirely, sometimes toward a growth hormone secretagogue, more often toward sleep or metabolic work first.
No page can tell you which one applies to you. The prescribing provider makes that call after intake, and Baseline consultants help you prepare for that conversation.
What gets measured
A useful hormone panel usually includes total and free testosterone, SHBG, estradiol, thyroid markers and morning cortisol. The reason for the breadth is that hypothyroidism, poor sleep, low iron and low testosterone produce a similar complaint, and the panel is what separates them.
For replacement therapy, HRT and TRT, lab work comes first. A provider does not prescribe hormones without it, and the diagnosis of low testosterone itself depends on repeat morning measurements. Lab work can be arranged through our provider network. Once a protocol is underway we recommend repeat labs quarterly, so the plan is judged on measurements rather than impressions.
What this means for you
Decide which question you are asking before you shop for a therapy. Replacing a hormone you no longer make and prompting your own production are different decisions with different evidence, and the panel usually tells you which conversation to have.
Therapies discussed here
Common questions
What is the difference between HRT, TRT and a growth hormone peptide?
They act on different systems. HRT and TRT replace a hormone the body no longer makes at its former level, estrogen and progesterone in the first case, testosterone in the second. Growth hormone secretagogues such as sermorelin and tesamorelin replace nothing: they prompt the pituitary to release more of your own growth hormone.
Which one would a provider consider for me?
It follows the symptom and lab pattern. Menopausal symptoms point toward HRT, confirmed low testosterone toward TRT, and body composition or recovery complaints with normal sex hormones usually point toward sleep and metabolic work before anything else. The prescribing provider decides after intake.
Do I need labs before hormone work?
For HRT and TRT, yes. Replacement therapy starts with lab work, and a provider will not prescribe it without a panel in front of them. For a growth hormone secretagogue such as sermorelin, labs are strongly recommended rather than required. Either way we recommend repeat labs quarterly once a protocol is underway, and lab work can be arranged through our provider network.
Is hormone optimization the same thing as anti-aging?
No, and the two get conflated constantly in marketing. Hormone work addresses a measurable deficiency or a symptomatic transition. It has not been shown to extend lifespan, and the evidence does not support selling it that way.
References
- Bhasin S, et al., Testosterone therapy in men with hypogonadism, Endocrine Society clinical practice guideline, JCEM, 2018
- The 2022 hormone therapy position statement of The North American Menopause Society, Menopause, 2022
- Falutz J, et al., Tesamorelin for HIV-associated lipodystrophy, New England Journal of Medicine, 2007
- Biomarker hub: Free vs total testosterone